15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $103M | $38M | 92.7% | 7.1% | $2M | $46M | $17M |
| 2024 | $87M | $10M | 90.6% | 1.5% | -$229632 | $31M | $16M |
| 2023 | $65M | $4M | 87.9% | -6.5% | -$4M | $10M | $5M |
| 2022 | $46M | -$8M | 86.1% | -27.3% | -$6M | — | $9M |
| 2021 | $24M | -$8M | 90.4% | -30.6% | -$5M | — | $19M |
| 2020 | $16M | -$4M | 89.6% | -32.3% | -$5M | — | $455366 |
| 2019 | — | -$3M | — | — | -$2M | $0 | $7M |
| 2018 | — | -$600574 | — | — | $268660 | — | $176421 |
| 2017 | — | $331309 | — | — | -$183757 | — | $463189 |
| 2016 | — | -$415747 | — | — | $406216 | — | $833480 |
| 2015 | — | -$1M | — | — | -$1M | — | $182337 |
| 2014 | — | -$2M | — | — | -$2M | — | $523441 |
| 2013 | — | -$4M | — | — | -$2M | — | $44553 |
| 2012 | — | -$2M | — | — | — | — | $45861 |
| 2011 | — | -$13M | — | — | — | — | $3608 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $28M | $458957 | 93.1% | 9.5% | -$3M | $46M | $14M |
| Dec '25 | $28M | -$2M | 93.2% | 3.8% | $4M | $46M | $17M |
| Sep '25 | $26M | -$30M | 92.9% | 11.2% | $1M | $45M | $15M |
| Jun '25 | $26M | -$2M | 92.5% | -0.1% | $902652 | $44M | $17M |
| Mar '25 | $23M | -$4M | 92.2% | 3.5% | -$4M | $43M | $21M |
| Dec '24 | $26M | -$2M | 91.4% | 8.6% | $859875 | $31M | $16M |
| Sep '24 | $22M | -$3M | 90.8% | 3.6% | $2M | $30M | $16M |
| Jun '24 | $20M | -$4M | 90.0% | -14.3% | -$1M | $14M | $6M |
| Mar '24 | $19M | -$2M | 89.8% | -8.3% | -$2M | $10M | $3M |
| Dec '23 | $18M | -$237194 | 89.9% | -1.3% | -$902808 | $10M | $5M |
| Sep '23 | $16M | -$1M | 89.1% | -5.7% | $893818 | $10M | $6M |
| Jun '23 | $16M | -$2M | 86.1% | -11.8% | -$2M | — | $6M |
| Mar '23 | $16M | -$1M | 86.3% | -7.8% | -$2M | — | $7M |
| Dec '22 | $15M | -$4M | 84.5% | -20.4% | -$698380 | — | $9M |
| Sep '22 | $13M | -$1M | 82.9% | -24.8% | -$2M | — | $10M |
| Jun '22 | $10M | $769426 | 90.1% | -35.0% | -$1M | — | $13M |
| Mar '22 | $8M | -$3M | 89.7% | -35.5% | -$2M | — | $16M |
| Dec '21 | $7M | -$3M | 88.9% | -48.5% | -$2M | — | $19M |
| Sep '21 | $6M | -$2M | 91.1% | -31.8% | -$1M | — | $22M |
| Jun '21 | $6M | -$1M | 91.5% | -16.3% | -$355346 | — | $24M |
How the market has priced SMTI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Sanara MedTech Inc.'s revenue has grown 45.9% per year. These are computed facts, not advice.
As of FY2025, Sanara MedTech Inc. reported $46M of total debt against $17M of cash; operating income covered interest expense 1.1×.
In FY2025, gross margin was 92.7%, operating margin 7.1%, and net margin 36.4%.
As of Jun '26, Sanara MedTech Inc. traded at a price-to-earnings ratio of about 5.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.